Valacyclovir hydrochloride and Hepatocellular injury - a phase IV clinical study of FDA data

Summary:

Hepatocellular injury is found among people who take Valacyclovir hydrochloride, especially for people who are female, 60+ old, have been taking the drug for < 1 month.

The phase IV clinical study analyzes which people take Valacyclovir hydrochloride and have Hepatocellular injury. It is created by eHealthMe based on reports of 2,137 people who have side effects when taking Valacyclovir hydrochloride from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.



On May, 16, 2022

2,137 people reported to have side effects when taking Valacyclovir hydrochloride.
Among them, 22 people (1.03%) have Hepatocellular injury.


What is Valacyclovir hydrochloride?

Valacyclovir hydrochloride has active ingredients of valacyclovir hydrochloride. It is often used in herpes zoster. eHealthMe is studying from 2,296 Valacyclovir hydrochloride users for its effectiveness, alternative drugs and more.

What is Hepatocellular injury?

Hepatocellular injury (liver injury) is found to be associated with 927 drugs and 843 conditions by eHealthMe.

Number of Valacyclovir hydrochloride and Hepatocellular injury reports submitted per year:

Could Valacyclovir hydrochloride cause Hepatocellular injury?

Time on Valacyclovir hydrochloride when people have Hepatocellular injury *:

  • < 1 month: 50 %
  • 1 - 6 months: 25 %
  • 6 - 12 months: 25 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Hepatocellular injury when taking Valacyclovir hydrochloride *:

  • female: 57.14 %
  • male: 42.86 %

Age of people who have Hepatocellular injury when taking Valacyclovir hydrochloride *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 19.05 %
  • 40-49: 0.0 %
  • 50-59: 23.81 %
  • 60+: 57.14 %

Common drugs people take besides Valacyclovir hydrochloride *:

  1. Bactrim: 8 people, 36.36%
  2. Noxafil: 8 people, 36.36%
  3. Piperacillin And Tazobactam: 4 people, 18.18%
  4. Emend: 4 people, 18.18%
  5. Crestor: 3 people, 13.64%
  6. Polaramine: 3 people, 13.64%
  7. Amlodipine: 3 people, 13.64%
  8. Vyxeos: 3 people, 13.64%
  9. Iclusig: 3 people, 13.64%
  10. Exjade: 3 people, 13.64%

Common side effects people have besides Hepatocellular injury *:

  1. Cholestasis (a condition where bile cannot flow from the liver to the duodenum): 5 people, 22.73%
  2. Dehydration (dryness resulting from the removal of water): 4 people, 18.18%
  3. Breathing Difficulty: 3 people, 13.64%
  4. Dizziness: 3 people, 13.64%
  5. Fluid Overload (too much fluid in the blood): 3 people, 13.64%
  6. Clostridium Difficile Colitis (inflammation of colon by clostridium difficile bacteria infection): 3 people, 13.64%
  7. Gastroenteritis Rotavirus (inflammation of stomach and intestine caused by a rotavirus infection): 3 people, 13.64%
  8. Formication (a sensation that exactly resembles that of small insects crawling on (or under) the skin): 3 people, 13.64%
  9. Ascites (accumulation of fluid in the abdominal cavity): 3 people, 13.64%
  10. High Blood Pressure: 3 people, 13.64%

Common conditions people have *:

  1. High Blood Pressure: 5 people, 22.73%
  2. High Blood Cholesterol: 4 people, 18.18%
  3. Iron Overload: 3 people, 13.64%
  4. Infection: 3 people, 13.64%
  5. Fungal Infection: 3 people, 13.64%
  6. Fever: 3 people, 13.64%
  7. Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 3 people, 13.64%
  8. Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 3 people, 13.64%
  9. Ocular Hypertension (intraocular pressure higher than normal): 2 people, 9.09%
  10. Mantle Cell Lymphoma Stage Iv (cancer of lymphocytes, a type of white blood cell, spreads to other part of body): 2 people, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Valacyclovir hydrochloride and have Hepatocellular injury?

Check whether Hepatocellular injury is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of Valacyclovir hydrochloride:

Hepatocellular injury treatments and more:

COVID vaccines that are related to Hepatocellular injury:

How severe was Hepatocellular injury and when was it recovered:

Expand to all the drugs that have ingredients of valacyclovir hydrochloride:

Common drugs associated with Hepatocellular injury:

All the drugs that are associated with Hepatocellular injury:

Common conditions associated with Hepatocellular injury:

All the conditions that are associated with Hepatocellular injury:

How the study uses the data?

The study uses data from the FDA. It is based on valacyclovir hydrochloride (the active ingredients of Valacyclovir hydrochloride) and Valacyclovir hydrochloride (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: